No subcontract or supplier opportunities available

The contract is a sole-source procurement awarded directly to Repligen Corporation for the supply of replacement components specifically designed to be compatible with proprietary ATF Perfusion Systems and 5L Benchtop Glass Bioreactors. This procurement does not allow for any subcontracting or delegation to other suppliers, ensuring exclusivity in the supply chain. The contract is managed by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, with the place of performance located in Silver Spring. The solicitation was posted on May 20, 2026, with a response deadline set for May 27, 2026. Although no specific NAICS code or detailed organizational type is provided, the contract clearly restricts supplier opportunities, emphasizing direct engagement with Repligen Corporation. This arrangement safeguards proprietary technology compatibility and maintains strict control over replacement part provision to support critical bioreactor systems used within the agency’s operations.